JP2008513367A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008513367A5 JP2008513367A5 JP2007531313A JP2007531313A JP2008513367A5 JP 2008513367 A5 JP2008513367 A5 JP 2008513367A5 JP 2007531313 A JP2007531313 A JP 2007531313A JP 2007531313 A JP2007531313 A JP 2007531313A JP 2008513367 A5 JP2008513367 A5 JP 2008513367A5
- Authority
- JP
- Japan
- Prior art keywords
- apo2l
- antibody
- medicament according
- trail polypeptide
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60790904P | 2004-09-08 | 2004-09-08 | |
| US66655305P | 2005-03-30 | 2005-03-30 | |
| PCT/US2005/031907 WO2006029224A2 (en) | 2004-09-08 | 2005-09-07 | Methods of using death receptor ligands and cd20 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008513367A JP2008513367A (ja) | 2008-05-01 |
| JP2008513367A5 true JP2008513367A5 (https=) | 2008-11-13 |
Family
ID=35788048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007531313A Pending JP2008513367A (ja) | 2004-09-08 | 2005-09-07 | デスレセプターリガンド及びｃｄ２０抗体の使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20090317384A1 (https=) |
| EP (1) | EP1791864A2 (https=) |
| JP (1) | JP2008513367A (https=) |
| KR (1) | KR20070050950A (https=) |
| AU (1) | AU2005282440A1 (https=) |
| BR (1) | BRPI0515615A (https=) |
| CA (1) | CA2577823A1 (https=) |
| IL (1) | IL181316A0 (https=) |
| MX (1) | MX2007002855A (https=) |
| NO (1) | NO20071790L (https=) |
| NZ (1) | NZ553174A (https=) |
| RU (1) | RU2007112929A (https=) |
| WO (1) | WO2006029224A2 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7361341B2 (en) | 2001-05-25 | 2008-04-22 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to trail receptors |
| US7348003B2 (en) | 2001-05-25 | 2008-03-25 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors |
| ES2672640T3 (es) | 2003-11-05 | 2018-06-15 | Roche Glycart Ag | Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas |
| AU2005227322A1 (en) | 2004-03-23 | 2005-10-06 | Biogen Idec Ma Inc. | Receptor coupling agents and therapeutic uses thereof |
| GB0524316D0 (en) * | 2005-11-29 | 2006-01-04 | Medical Res Council | Tumour necrosis factor-related apoptosis-inducing ligands (TRAILs) |
| BRPI0718413A2 (pt) | 2006-10-23 | 2014-03-11 | The Uab Research Foundation | Métodos para prever a sensibilidade de uma célula concerosa a um primeiro agente anticâncer, para prever ou monitorar a eficácia de um agente anticâncer, e para determinar uma dose eficaz para um agente anticâncer, kit de detecção, e, sistema de ensaio multiplex |
| WO2009020094A1 (ja) * | 2007-08-09 | 2009-02-12 | Daiichi Sankyo Company, Limited | 疎水性分子で修飾した抗体 |
| TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
| WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
| WO2011028961A2 (en) | 2009-09-04 | 2011-03-10 | Xoma Technology Ltd. | Anti-botulism antibody coformulations |
| WO2011028962A1 (en) * | 2009-09-04 | 2011-03-10 | Xoma Technology Ltd. | Antibody coformulations |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| TW201129384A (en) | 2010-02-10 | 2011-09-01 | Immunogen Inc | CD20 antibodies and uses thereof |
| US20140178398A1 (en) * | 2011-05-03 | 2014-06-26 | Genentech, Inc | Vascular disruption agents and uses thereof |
| US11299528B2 (en) | 2014-03-11 | 2022-04-12 | D&D Pharmatech Inc. | Long acting TRAIL receptor agonists for treatment of autoimmune diseases |
| SG11201706024YA (en) | 2015-01-26 | 2017-08-30 | Macrogenics Inc | Multivalent molecules comprising dr5-binding domains |
| WO2017106627A1 (en) | 2015-12-17 | 2017-06-22 | The Johns Hopkins University | Ameliorating systemic sclerosis with death receptor agonists |
| KR102508650B1 (ko) * | 2016-04-07 | 2023-03-13 | 더 존스 홉킨스 유니버시티 | 사멸 수용체 작용제로써 췌장암 및 통증을 치료하기 위한 조성물 및 방법 |
| US10610104B2 (en) | 2016-12-07 | 2020-04-07 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| US20210138213A1 (en) | 2017-03-30 | 2021-05-13 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| KR102532779B1 (ko) * | 2017-09-08 | 2023-05-16 | 한국생명공학연구원 | Ddias 억제제 및 사멸 수용체 리간드를 포함하는 암의 예방 또는 치료용 조성물 |
| US12227565B2 (en) | 2018-06-20 | 2025-02-18 | Biora Therapeutics, Inc. | Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine |
| WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| US20220249814A1 (en) | 2018-11-19 | 2022-08-11 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| US11767353B2 (en) | 2020-06-05 | 2023-09-26 | Theraly Fibrosis, Inc. | Trail compositions with reduced immunogenicity |
| KR20240102971A (ko) | 2021-11-16 | 2024-07-03 | 제넨테크, 인크. | 모수네투주맙을 이용하여 전신 홍반성 루푸스(sle)를 치료하기 위한 방법과 조성물 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5871996A (en) * | 1994-02-04 | 1999-02-16 | Bio Merieux | Retrovirus agents MSRV1 and MSRV2 associated with multiple sclerosis |
| IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| AU708239B2 (en) * | 1995-06-29 | 1999-07-29 | Immunex Corporation | Cytokine that induces apoptosis |
| US6998116B1 (en) * | 1996-01-09 | 2006-02-14 | Genentech, Inc. | Apo-2 ligand |
| US6030945A (en) * | 1996-01-09 | 2000-02-29 | Genentech, Inc. | Apo-2 ligand |
| US6342363B1 (en) * | 1997-01-28 | 2002-01-29 | Human Genome Sciences, Inc. | Death domain containing receptor 4 nucleic acids and methods |
| US6433147B1 (en) * | 1997-01-28 | 2002-08-13 | Human Genome Sciences, Inc. | Death domain containing receptor-4 |
| US6072047A (en) * | 1997-02-13 | 2000-06-06 | Immunex Corporation | Receptor that binds trail |
| US20020160446A1 (en) * | 2000-11-14 | 2002-10-31 | Holtzman Douglas A. | Novel genes encoding proteins having prognostic diagnostic preventive therapeutic and other uses |
| US20010010924A1 (en) * | 1997-03-14 | 2001-08-02 | Keith Charles Deen | Tumor necrosis factor related receptor, tr6 polynecleotides |
| CN1624128A (zh) * | 1997-03-17 | 2005-06-08 | 人类基因组科学公司 | 包含死亡结构域的受体－5 |
| US6872568B1 (en) * | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
| WO1998046643A1 (en) * | 1997-04-16 | 1998-10-22 | Millennium Biotherapeutics, Inc. | TUMOR NECROSIS FACTOR RECEPTOR RELATED PROTEINS TANGO-63d AND TANGO-63e |
| US6342369B1 (en) * | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
| JPH11162958A (ja) * | 1997-09-16 | 1999-06-18 | Tokyo Electron Ltd | プラズマ処理装置及びその方法 |
| US6252050B1 (en) * | 1998-06-12 | 2001-06-26 | Genentech, Inc. | Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method |
| US7071300B2 (en) * | 2001-03-14 | 2006-07-04 | Genentech, Inc. | IGF antagonist peptides |
| IL161051A0 (en) * | 2001-10-02 | 2004-08-31 | Genentech Inc | Apo-2 ligand variants and uses thereof |
| CN100506277C (zh) * | 2001-11-01 | 2009-07-01 | Uab研究基金会 | 肿瘤坏死因子相关细胞凋亡诱导配体受体的选择性抗体和其它治疗剂的联合体系 |
| AU2002346373A1 (en) * | 2001-11-09 | 2003-05-19 | Idec Pharmaceuticals Corporation | Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies |
| CA2489348A1 (en) * | 2002-06-24 | 2003-12-31 | Genentech, Inc. | Apo-2 ligand/trail variants and uses thereof |
-
2005
- 2005-09-07 BR BRPI0515615-7A patent/BRPI0515615A/pt not_active IP Right Cessation
- 2005-09-07 CA CA002577823A patent/CA2577823A1/en not_active Abandoned
- 2005-09-07 MX MX2007002855A patent/MX2007002855A/es not_active Application Discontinuation
- 2005-09-07 JP JP2007531313A patent/JP2008513367A/ja active Pending
- 2005-09-07 EP EP05794923A patent/EP1791864A2/en not_active Withdrawn
- 2005-09-07 RU RU2007112929/13A patent/RU2007112929A/ru not_active Application Discontinuation
- 2005-09-07 US US11/662,314 patent/US20090317384A1/en not_active Abandoned
- 2005-09-07 NZ NZ553174A patent/NZ553174A/en not_active IP Right Cessation
- 2005-09-07 WO PCT/US2005/031907 patent/WO2006029224A2/en not_active Ceased
- 2005-09-07 AU AU2005282440A patent/AU2005282440A1/en not_active Abandoned
- 2005-09-07 KR KR1020077005374A patent/KR20070050950A/ko not_active Withdrawn
-
2006
- 2006-10-03 US US11/542,528 patent/US20080044421A1/en not_active Abandoned
-
2007
- 2007-02-13 IL IL181316A patent/IL181316A0/en unknown
- 2007-04-04 NO NO20071790A patent/NO20071790L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008513367A5 (https=) | ||
| Park et al. | Eosinophil survival and apoptosis in health and disease | |
| RU2007112929A (ru) | Способы применения лигандов рецептора смерти и антител к cd20 | |
| US12552856B2 (en) | Anti-PCRV antibodies that bind PCRV, compositions comprising anti-PCRV antibodies, and methods of use thereof | |
| US11779631B2 (en) | CD47 blockade therapy by HDAC inhibitors | |
| TW201641104A (zh) | Ｉｌ－１７抗體之醫藥產品及穩定之液體組合物 | |
| CN109789196A (zh) | 用于通过施用il-4r拮抗剂来预防或治疗变态反应的方法 | |
| EP1921090A4 (en) | COMPOSITION OF GENETICALLY MODIFIED ANTIBODY | |
| JP2009519257A5 (https=) | ||
| CN1047035A (zh) | 生物应答修饰因子的新颖抗体传递系统 | |
| JP2015520188A5 (https=) | ||
| JP2021193121A (ja) | Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法 | |
| US20200237822A1 (en) | Compositions and methods for stimulating natural killer cells | |
| ES2992409T3 (es) | Métodos de tratamiento de la psoriasis en placas de nueva aparición usando antagonistas de IL-17 | |
| ES2860480T3 (es) | Anticuerpos neutralizantes de GM-CSF para su uso en el tratamiento de la artritis reumatoide o como analgésicos | |
| US20240392019A1 (en) | Anti-il-36r antibodies for the treatment of neutrophilic dermatoses | |
| EP4268803A1 (en) | Stable antibody preparation, preparation method for same, and applications thereof | |
| JP2011506436A (ja) | 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 | |
| CN116406290A (zh) | 用于治疗慢性炎症性疼痛的抗il-36r抗体 | |
| CN101671390A (zh) | 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途 | |
| CN115666643A (zh) | 用于治疗异位性皮肤炎的抗il-36r抗体 | |
| AU2019235627A1 (en) | Improvements in CD47 blockade therapy by EGFR antibody | |
| JP2014526440A5 (https=) | ||
| Weigelt et al. | Pharmacokinetic evaluation of palifermin for mucosal protection from chemotherapy and radiation | |
| JP4629964B2 (ja) | ウシの消化器疾患治療剤 |